TDXD and HER2 Low Hormone Receptor Negative Breast Cancer

In triple negative breast cancer, certainly we have approval for SACITU, ZIMAP, GOVETE, TKAN. That's our trope to directed antibody drug conjugate. And that's for patients who've had, you know, it can be used in the second line and beyond metastatic setting essentially. What also came by from the destiny O4 trial and led to its approval was for patients with HR negative HER2 low. We saw a very robust improvement in progression free survival and overall survival benefit.